

Treatment and Antimicrobial Stewardship with New Agents

June 1, 2024 to May 31, 2025

This activity is accredited for one year from June 1, 2024 to May 31, 2025. Learners can claim Continuing Education credit via this activity evaluation; MAD-ID will send credits for pharmacy learners to CE Monitor within four weeks thereafter. The evaluation will close June 30, 2025 and the final upload of credits will happen before July 31, 2025. Learners claiming AMA PRA Category 1 Credits™ can expect to receive PDF certificates via email in a similar timeframe. Please reach out to info@mad-id.org with any questions or specific requests.

The types of CE available for “Treatment and Antimicrobial Stewardship with New Agents” include:

Continuing Pharmacy Education: Making a Difference in Infectious Diseases (MAD-ID) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. MAD-ID designates this enduring activity for 1.00 contact hours or 0.1 CEU. Participants should claim only the credit commensurate with the extent of their participation in the activity. UAN #: 0485-0000-24-003-H01-P

Continuing Medical Education: This activity has been planned and implemented in accordance with the accreditation requirement and policies of the Accreditation Council for Continuing Medical Education (ACCME). Making a Difference in Infectious Diseases (MAD-ID) is accredited by the ACCME to provide continuing medical education for physicians. MAD-ID designates this enduring activity for a maximum of 1.00 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

In accord with the disclosure policy of MAD-ID and the *Standards for Integrity and Independence Accreditation Criteria* adopted by the ACPE and ACCME, course planners, speakers, and content reviewers have been asked to disclose any relationship they have with companies producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients.

Such disclosure is not intended to suggest or condone bias in any presentation but is solicited to provide the course director and participants with information that might be of potential importance to their evaluation of a given presentation. The following planners, speakers, and content reviewers have reported financial relationships with an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients:

NAME	COMPANY	RELATIONSHIP
Course Planners:		
Michael Rybak PharmD, MPH, PhD, FCCP, FIDSA, FIDP	AbbVie	Research Support, Honoraria and Advisory Committee/Board
	Innovia	Research Support, Honoraria

NAME	COMPANY	RELATIONSHIP
Course Planners (cont'd):		
Michael Rybak PharmD, MPH, PhD, FCCP, FIDSA, FIDP	Merck	Research Support and Advisory Committee/Board
	Melinta	Research Support
	Paratek	Research Support
	Shionogi, Inc.	Research Support, Honoraria and Advisory Committee/Board
	Ferring T2 Biosystems	Advisory Committee/Board Research Support and Advisory Committee/Board
Kerry LaPlante, PharmD, FCCP, FIDSA, FIDP	Pfizer	Research Support
	Melinta	Research Support and Consulting
	AbbVie	Research Support
	Entasis	Research Support
	Shionogi, Inc.	Consulting
	Basilea Ferring	Consulting Consulting

All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have reported no financial relationships related to the content of this activity.

ACTIVITY COMMERCIAL SUPPORT

This activity is supported by an educational grant from Shionogi, Inc.